{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:05:51Z","timestamp":1795104351956,"version":"4.10.3"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NP Pharma"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Kratom use is rising, increasing the need for safety and tolerability studies of high-quality and well-characterized kratom products in humans. Kratom's risk\u2013benefit ratio, recommended dose, treatment-emergent adverse events (TEAEs), abuse potential, and withdrawal require evaluation. Thus, the safety and tolerability of 4 escalating single and 15 daily dried kratom leaf powder doses in human volunteers were evaluated over 47 days in the largest controlled kratom-administration study to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A randomized, between-subject, double-blind, placebo-controlled, dose-escalation study of MitraLeaf kratom powder after single doses (SD), during 15 daily doses (multiple doses; MD), and a 23-day follow-up was conducted in 116 volunteers (49 MitraLeaf and 67 placebo). Twelve participants each received a SD of either 6.65, 13.3, 26.6, or 53.2 mg (n = 13) mitragynine in 500, 1000, 2000, or 4000 mg of MitraLeaf, respectively, with a 10-day follow-up. The same participants received 15 daily doses at the same concentration of SD mitragynine received, with a 27-day follow-up period. Inclusion criteria were nonsmoking healthy males and females who never used kratom or had not used kratom for \u226512 months, 18\u201355 years old, and BMI \u226518.5 and \u226429.9 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Participants were excluded if they had known CYP3A4, CYP2D6, or CYP1A2 genetic polymorphisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>No serious adverse events or deaths were reported. TEAEs after SD or MD generally increased as the dose increased. Dizziness, nausea, and feeling of relaxation were the most commonly reported TEAEs after SD, and headache, feeling hot, increased alanine aminotransferase level, and nausea were most common after MD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      This SD and first MD controlled study shows that\n                      <jats:italic toggle=\"yes\">Mitragyna speciosa<\/jats:italic>\n                      \u2013derived MitraLeaf kratom powder was safe and well tolerated at the dose ranges tested, with no evidence of meaningful abuse potential or withdrawal.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001427","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:01:20Z","timestamp":1767589280000},"page":"665-675","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Safety and Tolerability of Single and Multiple Daily Oral Doses of Dried Kratom Leaf Powder in a Randomized Trial in Healthy Volunteers"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2137-4645","authenticated-orcid":false,"given":"Marilyn A.","family":"Huestis","sequence":"first","affiliation":[{"name":"Institute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bothmer","sequence":"additional","affiliation":[{"name":"JB Pharma Consulting, Heerlen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hudzik","sequence":"additional","affiliation":[{"name":"AlaBiopharma Consulting, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Henningfield","sequence":"additional","affiliation":[{"name":"PinneyAssociates, Bethesda, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibyl","family":"Swift","sequence":"additional","affiliation":[{"name":"NP Pharma, Marietta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neubiorev.2012.11.012","article-title":"From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction","volume":"37","author":"Hassan","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17512433.2024.2305798","article-title":"An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations","volume":"17","author":"McCurdy","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R3-20260911","article-title":"Kratom faces increasing scrutiny from states and the feds","author":"Hernandez","year":"2025","journal-title":"Stateline"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/0006-2952(67)90139-6","article-title":"The metabolism of corynantheidine and 9-methoxycory-nantheidine-type alkaloids by liver microsomes","volume":"16","author":"Beckett","year":"1967","journal-title":"Biochem Pharmacol"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/00498254.2018.1552819","article-title":"Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom)","volume":"49","author":"Kamble","year":"2019","journal-title":"Xenobiotica"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"597696","DOI":"10.3389\/fpls.2020.597696","article-title":"Effects of nutrient fertility on growth and alkaloidal content in Mitragyna speciosa (kratom)","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Plant Sci"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1021\/jacs.6b00360","article-title":"Synthetic and receptor signaling explorations of the Mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators","volume":"138","author":"Kruegel","year":"2016","journal-title":"J Am Chem Soc"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-013-3201-y","article-title":"Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract","volume":"231","author":"Stolt","year":"2014","journal-title":"Psychopharmacology"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","article-title":"Mitragynine\/Corynantheidine pseudoindoxyls as opioid analgesics with Mu agonism and Delta antagonism, which do not recruit \u03b2-Arrestin-2","volume":"59","author":"V\u00e1radi","year":"2016","journal-title":"J Med Chem"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40122-020-00151-x","article-title":"Kratom-pharmacology, clinical implications, and outlook: a comprehensive review","volume":"9","author":"Eastlack","year":"2020","journal-title":"Pain Ther"},{"key":"R12-20260911","first-page":"145","article-title":"Some observations on the pharmacology of mitragynine","volume":"198","author":"Macko","year":"1972","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1007\/s00213-022-06244-z","article-title":"Respiratory effects of oral mitragynine and oxycodone in a rodent model","volume":"239","author":"Henningfield","year":"2022","journal-title":"Psychopharmacology"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"775073","DOI":"10.3389\/fphar.2021.775073","article-title":"Kratom abuse potential 2021: an updated eight factor analysis","volume":"12","author":"Henningfield","year":"2021","journal-title":"Front Pharmacol"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"100142","DOI":"10.1016\/j.dadr.2023.100142","article-title":"Kratom withdrawal: discussions and conclusions of a scientific expert forum","volume":"7","author":"Henningfield","year":"2023","journal-title":"Drug Alcohol Depend Rep"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0014-2999(96)00714-5","article-title":"Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems","volume":"317","author":"Matsumoto","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.lfs.2004.10.086","article-title":"Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa","volume":"78","author":"Matsumoto","year":"2005","journal-title":"Life Sci"},{"key":"R18-20260911","first-page":"792","article-title":"Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects","volume":"112","author":"Prozialeck","year":"2012","journal-title":"J Am Osteopath Assoc"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acs.jmedchem.9b01465","article-title":"Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids","volume":"63","author":"Obeng","year":"2020","journal-title":"J Med Chem"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"13510","DOI":"10.1021\/acs.jmedchem.1c00726","article-title":"Activity of Mitragyna speciosa (\u201ckratom\u201d) alkaloids at serotonin receptors","volume":"64","author":"Le\u00f3n","year":"2021","journal-title":"J Med Chem"},{"key":"R21-20260911","first-page":"2421","article-title":"Pharmacokinetics of mitragynine in man","volume":"9","author":"Trakulsrichai","year":"2015","journal-title":"Drug Des Dev Ther"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3390\/pharmaceutics14030620","article-title":"Clinical pharmacokinetic assessment of kratom (Mitragyna speciosa), a botanical product with opioid-like effects, in healthy adult participants","volume":"14","author":"Tanna","year":"2022","journal-title":"Pharmaceutics"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1124\/dmd.122.001005","article-title":"Translating kratom-drug interactions: from bedside to bench and back","volume":"51","author":"Tanna","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cpdd.394","article-title":"Categorization of abuse potential-related adverse events","volume":"7","author":"Sellers","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R26-20260911","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/ajad.12862","article-title":"Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment","volume":"28","author":"Kosten","year":"2019","journal-title":"Am J Addict"},{"key":"R27-20260911","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/heart.89.3.353","article-title":"Differential diagnosis of cardiogenic syncope and seizure disorders","volume":"89","author":"Bergfeldt","year":"2003","journal-title":"Heart"},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/molecules29050984","article-title":"Human mitragynine and 7-hydroxy-mitragynine pharmacokinetics after single and multiple daily doses of oral encapsulated dried kratom leaf powder","volume":"29","author":"Huestis","year":"2024","journal-title":"Molecules"},{"key":"R30-20260911","doi-asserted-by":"crossref","first-page":"1403140","DOI":"10.3389\/fphar.2024.1403140","article-title":"Kratom safety and toxicology in the public health context: research needs to better inform regulation","volume":"15","author":"Henningfield","year":"2024","journal-title":"Front Pharmacol"},{"key":"R32-20260911","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2023.04.026","article-title":"Kratom-induced acute liver injury: a case study and the importance of herbal supplement regulation","volume":"79","author":"Roma","year":"2023","journal-title":"J Hepatol"},{"key":"R33-20260911","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/ajg.2016.114","article-title":"Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury","volume":"111","author":"Hillman","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R34-20260911","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s13181-011-0155-5","article-title":"Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa)","volume":"7","author":"Kapp","year":"2011","journal-title":"J Med Toxicol"},{"key":"R35-20260911","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/gr990e","article-title":"Histologic characterization of kratom use-associated liver injury","volume":"11","author":"Riverso","year":"2018","journal-title":"Gastroenterol Res"},{"key":"R36-20260911","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14740\/gr1204","article-title":"Kratom-induced cholestatic liver injury mimicking anti-mitochondrial antibody-negative primary biliary cholangitis: a case report and review of literature","volume":"12","author":"Aldyab","year":"2019","journal-title":"Gastroenterol Res"},{"key":"R37-20260911","doi-asserted-by":"crossref","first-page":"2324709619836138","DOI":"10.1177\/2324709619836138","article-title":"Kratom-induced cholestatic liver injury and its conservative management","volume":"7","author":"Fernandes","year":"2019","journal-title":"J Investig Med High Impact Case Rep"},{"key":"R38-20260911","doi-asserted-by":"crossref","first-page":"2324709619826167","DOI":"10.1177\/2324709619826167","article-title":"Drug-induced liver injury caused by kratom use as an alternative pain treatment amid an ongoing opioid epidemic","volume":"7","author":"Osborne","year":"2019","journal-title":"J Investig Med High Impact Case Rep"},{"key":"R39-20260911","first-page":"e14679","article-title":"Kratom-induced liver injury: a case series and clinical implications","volume":"13","author":"Botejue","year":"2021","journal-title":"Cureus"},{"key":"R40-20260911","doi-asserted-by":"crossref","first-page":"108426","DOI":"10.1016\/j.drugalcdep.2020.108426","article-title":"Liver injury associated with kratom, a popular opioid-like product: experience from the U.S. drug induced liver injury network and a review of the literature","volume":"218","author":"Ahmad","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"R41-20260911","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1080\/17425255.2025.2577677","article-title":"Modifying Hy's law and eDISH for the modern idiosyncratic DILI era","volume":"21","author":"Cohen","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:27Z","timestamp":1789135227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001427","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"2025-08-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}